MGX Metagenomi, Inc.

Nasdaq metagenomi.co


$ 2.49 $ -0.13 (-4.96 %)    

Wednesday, 29-Oct-2025 12:12:42 EDT
QQQ $ 634.37 $ -1.18 (-0.19 %)
DIA $ 479.60 $ 0.99 (0.21 %)
SPY $ 687.87 $ -0.87 (-0.13 %)
TLT $ 91.73 $ -0.15 (-0.16 %)
GLD $ 367.73 $ -1.90 (-0.51 %)
$ 2.63
$ 2.63
$ 2.47 x 300
$ 2.49 x 100
$ 2.47 - $ 2.63
$ 1.23 - $ 4.92
643,467
na
98.71M
$ 1.00
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-12-2025 06-30-2025 10-Q
2 05-13-2025 03-31-2025 10-Q
3 03-17-2025 12-31-2024 10-K
4 11-13-2024 09-30-2024 10-Q
5 08-14-2024 06-30-2024 10-Q
6 05-14-2024 03-31-2024 10-Q
7 03-27-2024 12-31-2023 10-K
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

Core News & Articles
Metagenomi Shares Resume Trade
10/16/2025 15:48:36

Core News & Articles

HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Metagenomi (NASDAQ:MGX) with a Buy and maintains $7 price target.

Core News & Articles

Chardan Capital analyst Geulah Livshits maintains Metagenomi (NASDAQ:MGX) with a Buy and lowers the price target from $12 to...

Core News & Articles

Wells Fargo analyst Yanan Zhu maintains Metagenomi (NASDAQ:MGX) with a Overweight and lowers the price target from $16 to $12.

 sam-altman-says-he-didnt-think-elon-musk-would-abuse-government-power-tesla-ceo-hits-back-with-scam-altman-jibe

OpenAI CEO Sam Altman regrets underestimating Elon Musk's potential abuse of power to block OpenAI's $500B Stargate dea...

 eli-lillys-13-billion-verve-deal-signals-confidence-in-gene-editing-space-analyst

Lilly's Verve acquisition lifts sentiment in gene editing stocks, with analysts calling it a strategic and timely move in a...

Core News & Articles

Chardan Capital analyst Geulah Livshits maintains Metagenomi (NASDAQ:MGX) with a Buy and lowers the price target from $13 to...

Core News & Articles

Wells Fargo analyst Yanan Zhu maintains Metagenomi (NASDAQ:MGX) with a Overweight and lowers the price target from $20 to $16.

Core News & Articles

Potential best-in-class extrahepatic in vivo gene editing with all-in-one delivery to the central nervous system (CNS) is a cri...

Core News & Articles

Metagenomi (NASDAQ:MGX) reported quarterly losses of $(0.68) per share which missed the analyst consensus estimate of $(0.58) b...

Core News & Articles

HC Wainwright & Co. analyst Mitchell Kapoor maintains Metagenomi (NASDAQ:MGX) with a Buy and lowers the price target fro...

Core News & Articles

Wells Fargo analyst Yanan Zhu maintains Metagenomi (NASDAQ:MGX) with a Overweight and lowers the price target from $25 to $20.

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION